You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

crizotinib

Showing 1 - 25 of 77
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • (no location specified)
Oct 8, 2023

Metastatic Uveal Melanoma Trial in Grand Rapids (IDE196, Crizotinib, Pembrolizumab)

Recruiting
  • Metastatic Uveal Melanoma
  • Grand Rapids, Michigan
    The Cancer and Hematology Centers
Aug 14, 2023

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Crizotinib
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)

Active, not recruiting
  • Hematologic Cancers
  • +2 more
  • Crizotinib
  • Villejuif, Ile De France, France
    Gustave Roussy
Sep 5, 2022

Advanced Cancers Trial in Houston (Crizotinib, Dasatinib)

Completed
  • Advanced Cancers
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jun 29, 2022

Healthy Participants Trial in New Haven (Crizotinib)

Completed
  • Healthy Participants
  • Crizotinib
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Jan 18, 2022

Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) Trial in United States (Crizotinib)

Active, not recruiting
  • Neurofibromatosis 2
  • Progressive Vestibular Schwannoma (VS)
  • Crizotinib
  • Birmingham, Alabama
  • +16 more
Jan 3, 2023

First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous

Recruiting
  • Non-small Cell Lung Cancer
  • Crizotinib
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 1, 2022

First Line Crizotinib for ALK Rearranged Non-squamous Non-small

Recruiting
  • Non-small Cell Lung Cancer
  • Crizotinib
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 1, 2022

Lung Cancer, Nonsmall Cell Trial in Aurora (Crizotinib)

Completed
Has Results
  • Lung Cancer, Nonsmall Cell
  • Crizotinib
  • Aurora, Colorado
    University of Colorado Denver
Jan 19, 2022

NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Augusta, Georgia
  • +40 more
Nov 29, 2023

Glioblastoma Multiforme (Grade IV) of Cerebellum Trial in L'Hospitalet de Llobregat, Barcelona, Madrid (Crizotinib)

Completed
  • Glioblastoma Multiforme (Grade IV) of Cerebellum
  • Crizotinib
  • L'Hospitalet de Llobregat, Barcelona, Spain
  • +3 more
Mar 9, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Crizotinib
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Feb 4, 2022

Castration-resistant Prostate Cancer Trial in Boston (Crizotinib, Enzalutamide)

Completed
  • Castration-resistant Prostate Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 5, 2022

NSCLC Trial in Chang Chun (XZP-3621, Crizotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Chang Chun, Ji Lin, China
    Jilin Province Cancer Hospital
Jan 10, 2022

Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Oslo, Norway
    Pfizer Norway
Apr 17, 2023

ALK or ROS1-positive NSCLC Trial in China (Crizotinib)

Active, not recruiting
  • ALK or ROS1-positive NSCLC
  • Crizotinib
  • Fuzhou, Fujian, China
  • +9 more
Aug 30, 2022

Metastatic Colorectal Cancer Trial in Oslo (Alectinib, Cetuximab, Crizotinib)

Recruiting
  • Metastatic Colorectal Cancer
  • Oslo, Norway
    Oslo University Hospital
Feb 10, 2023

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial in Houston (Axitinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2021

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • crizotinib
  • +4 more
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

NSCLC Trial in Worldwide (Avelumab, PF-06463922, Crizotinib)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Atlanta, Georgia
  • +20 more
Jan 13, 2022

NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Avitinib Maleate
  • +13 more
  • Guangzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022

NSCLC Trial in Worldwide (Entrectinib, Crizotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Barretos, SP, Brazil
  • +66 more
Jan 27, 2023

Tumors Malignant Trial in Worldwide (Crizotinib)

Active, not recruiting
  • Neoplasms Malignant
  • Crizotinib
  • Fayetteville, Arkansas
  • +20 more
Oct 5, 2021

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

Completed
  • Non-small Cell Lung Cancer
  • Crizotinib
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 23, 2021